The U.S. has approved an oral Wegovy pill for weight management, launching January 5, 2026, with pricing from $149 to $299 monthly.

Now available in the United States is the oral Wegovy pill, which contains semaglutide. for adults who are overweight or obese, after receiving FDA approval in December 2025. It will launch on January 5, 2026, with a daily tablet option that costs between $149 and $299 per month, depending on dosage. Under a deal with the Trump administration, starter doses will cost less. It is necessary to take the medication on an empty stomach and refrain from eating or drinking for half an hour. More than 70,000 pharmacies and telehealth providers carry it. Similar weight loss and adverse effects, such as nausea and vomiting, are observed in clinical trials compared to the injectable version. Later in 2026, the FDA is anticipated to approve Eli Lilly's oral GLP-1 medication.